Introduction: Mucormycosis presents a diagnostic challenge characterized by high morbidity and mortality rates due to its swift and pervasive nature, which leads to extensive tissue destruction and dissemination. Immunocompromised individuals, notably those with hematological malignancies, are at a heightened risk. First-line antifungal agents include liposomal amphotericin B (L-AMB), posaconazole, and isavuconazole (IVZ), which offer advantages, such as minimal drug interactions and a favorable safety profile. However, the necessity and efficacy of therapeutic drug monitoring (TDM) of IVZ remain unclear. Case Presentation: We report a successful case of IVZ therapy in a patient who was intolerant of L-AMB, highlighting the efficacy and pharmacokinetics of IVZ in treating pulmonary mucormycosis. Pharmacokinetic analysis revealed steady plasma IVZ concentrations, emphasizing the importance of monitoring IVZ levels, particularly in patients undergoing renal replacement therapy. Conclusion: This case highlights the efficacy of IVZ therapy for mucormycosis and the potential utility of TDM in a specific patient population. Further research is needed to elucidate the optimal IVZ dosing and monitoring strategies to ensure safe and efficacious treatment.

1.
Cornely
OA
,
Alastruey-Izquierdo
A
,
Arenz
D
,
Chen
SCA
,
Dannaoui
E
,
Hochhegger
B
, et al
.
Global guideline for the diagnosis and management of mucormycosis: an initiative of the European confederation of medical mycology in cooperation with the mycoses study group education and research consortium
.
Lancet Infect Dis
.
2019
;
19
(
12
):
e405
21
.
2.
Rybak
JM
,
Marx
KR
,
Nishimoto
AT
,
Rogers
PD
.
Isavuconazole: pharmacology, pharmacodynamics, and current clinical experience with a new triazole antifungal agent
.
Pharmacotherapy
.
2015
;
35
(
11
):
1037
51
.
3.
Schmitt-Hoffmann
A
,
Desai
A
,
Kowalski
D
,
Pearlman
H
,
Yamazaki
T
,
Townsend
R
.
Isavuconazole absorption following oral administration in healthy subjects is comparable to intravenous dosing, and is not affected by food, or drugs that alter stomach pH
.
Int J Clin Pharmacol Ther
.
2016
;
54
(
8
):
572
80
.
4.
Patterson
TF
,
Thompson
GR
3rd
,
Denning
DW
,
Fishman
JA
,
Hadley
S
,
Herbrecht
R
, et al
.
Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America
.
Clin Infect Dis
.
2016
;
63
(
4
):
e1
60
.
5.
Abdul-Aziz
MH
,
Alffenaar
JWC
,
Bassetti
M
,
Bracht
H
,
Dimopoulos
G
,
Marriott
D
, et al
.
Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper
.
Intensive Care Med
.
2020
;
46
(
6
):
1127
53
.
6.
Furfaro
E
,
Signori
A
,
Di Grazia
C
,
Dominietto
A
,
Raiola
AM
,
Aquino
S
, et al
.
Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy
.
J Antimicrob Chemother
.
2019
;
74
(
8
):
2341
6
.
7.
Cojutti
PG
,
Carnelutti
A
,
Lazzarotto
D
,
Sozio
E
,
Candoni
A
,
Fanin
R
, et al
.
Population pharmacokinetics and pharmacodynamic target attainment of isavuconazole against Aspergillus fumigatus and Aspergillus flavus in adult patients with invasive fungal diseases: should therapeutic drug monitoring for isavuconazole Be considered as mandatory as for the other mold-active azoles
.
Pharmaceutics
.
2021
;
13
(
12
):
2099
.
8.
Kaindl
T
,
Andes
D
,
Engelhardt
M
,
Saulay
M
,
Larger
P
,
Groll
AH
.
Variability and exposure-response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases
.
J Antimicrob Chemother
.
2019
;
74
(
3
):
761
7
.
9.
Andes
D
,
Kovanda
L
,
Desai
A
,
Kitt
T
,
Zhao
M
,
Walsh
TJ
.
Isavuconazole concentration in real-world practice: consistency with results from clinical trials
.
Antimicrob Agents Chemother
.
2018
;
62
(
7
):
e00585-18
.
10.
Risum
M
,
Vestergaard
MB
,
Weinreich
UM
,
Helleberg
M
,
Vissing
NH
,
Jørgensen
R
.
Therapeutic drug monitoring of isavuconazole: serum concentration variability and success rates for reaching target in comparison with voriconazole
.
Antibiotics
.
2021
;
10
(
5
):
487
.
11.
Höhl
R
,
Bertram
R
,
Kinzig
M
,
Haarmeyer
GS
,
Baumgärtel
M
,
Geise
A
, et al
.
Isavuconazole therapeutic drug monitoring in critically ill ICU patients: a monocentric retrospective analysis
.
Mycoses
.
2022
;
65
(
7
):
747
52
.
12.
Perez
L
,
Corne
P
,
Pasquier
G
,
Konecki
C
,
Sadek
M
,
Le Bihan
C
, et al
.
Population pharmacokinetics of isavuconazole in critical care patients with COVID-19-associated pulmonary aspergillosis and Monte Carlo simulations of high off-label doses
.
J Fungi
.
2023
;
9
(
2
):
211
.
13.
Roden
MM
,
Zaoutis
TE
,
Buchanan
WL
,
Knudsen
TA
,
Sarkisova
TA
,
Schaufele
RL
, et al
.
Epidemiology and outcome of Zygomycosis: a review of 929 reported cases
.
Clin Infect Dis
.
2005
;
41
(
5
):
634
53
.
14.
Borman
AM
,
Hughes
JM
,
Oliver
D
,
Fraser
M
,
Sunderland
J
,
Noel
AR
, et al
.
Lessons from isavuconazole therapeutic drug monitoring at a United Kingdom Reference Center
.
Med Mycol
.
2020
;
58
(
7
):
996
9
.
15.
Cojutti
PG
,
Rinaldi
M
,
Giannella
M
,
Viale
P
,
Pea
F
.
Successful and safe real-time TDM-guided treatment of invasive pulmonary and cerebral aspergillosis using low-dose isavuconazole in a patient with primary biliary cirrhosis: grand round/A case study
.
Ther Drug Monit
.
2023
;
45
(
2
):
140
2
.
16.
Roberts
JA
,
Abdul-Aziz
MH
,
Lipman
J
,
Mouton
JW
,
Vinks
AA
,
Felton
TW
, et al
.
Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions
.
Lancet Infect Dis
.
2014
;
14
(
6
):
498
509
.
17.
Townsend
RW
,
Akhtar
S
,
Alcorn
H
,
Berg
JK
,
Kowalski
DL
,
Mujais
S
, et al
.
Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics
.
Eur J Clin Pharmacol
.
2017
;
73
(
6
):
669
78
.
18.
Yasu
T
,
Konuma
T
,
Kato
S
,
Kurokawa
Y
,
Takahashi
S
,
Tojo
A
.
Serum C-reactive protein levels affect the plasma voriconazole trough levels in allogeneic hematopoietic cell transplant recipients
.
Leuk Lymphoma
.
2017
;
58
(
11
):
2731
3
.
19.
Stanke-Labesque
F
,
Gautier-Veyret
E
,
Chhun
S
,
Guilhaumou
R
;
French Society of Pharmacology and Therapeutics
.
Inflammation is a major regulator of drug metabolizing enzymes and transporters: consequences for the personalization of drug treatment
.
Pharmacol Ther
.
2020
;
215
:
107627
.
20.
Fanos
V
,
Cataldi
L
.
Amphotericin B-induced nephrotoxicity: a review
.
J Chemother
.
2000
;
12
(
6
):
463
70
.
21.
Marty
FM
,
Ostrosky-Zeichner
L
,
Cornely
OA
,
Mullane
KM
,
Perfect
JR
,
Thompson
GR
, et al
.
Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis
.
Lancet Infect Dis
.
2016
;
16
(
7
):
828
37
.
22.
Silva
JT
,
Husain
S
,
Aguado
JM
.
Isavuconazole for treating invasive mould disease in solid organ transplant recipients
.
Transpl Int
.
2023
;
36
:
11845
.
23.
Desai
A
,
Kovanda
L
,
Kowalski
D
,
Lu
Q
,
Townsend
R
,
Bonate
PL
.
Population pharmacokinetics of isavuconazole from Phase 1 and Phase 3 (SECURE) trials in adults and target attainment in patients with invasive infections due to Aspergillus and other filamentous fungi
.
Antimicrob Agents Chemother
.
2016
;
60
(
9
):
5483
91
.
24.
Keirns
J
,
Desai
A
,
Kowalski
D
,
Lademacher
C
,
Mujais
S
,
Parker
B
, et al
.
QT interval shortening with isavuconazole: in vitro and in vivo effects on cardiac repolarization
.
Clin Pharmacol Ther
.
2017
;
101
(
6
):
782
90
.
You do not currently have access to this content.